FDA Drug recall D-0035-2020
Natpara (parathyroid hormone) for Injection, 25 mcg/dose, 2 pack cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NP…
- FDA Drug
- Class I
- terminated
- Published 2019-10-02
On 2019-10-02 the FDA classified a Class I recall of Natpara (parathyroid hormone) for Injection, 25 mcg/dose, 2 pack cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NP… by Shire Human Genetic Therapies, citing defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0035-2020 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2019-09-12 |
| Published | 2019-10-02 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Shire Human Genetic Therapies |
| Distribution | US |
Product
Natpara (parathyroid hormone) for Injection, 25 mcg/dose, 2 pack cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0202-02
Reason
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
Identifiers
| code_info | 08569357, exp 4/30/2020; 07983652, 08544833, exp 6/30/2021 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0035-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.